Entera Bio Presents Preclinical Data For OPK-8801003, Oral GLP-2 Tablet With Longer Half-Life Aiming To Replace Daily Injections For Short Bowel Syndrome Patients

Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2 Therapy

Oral GLP-2 Tablet Could Transform Treatment Paradigm for 30,000 Short Bowel Syndrome (SBS) Patients Currently Dependent on Daily Injections of the Peptide

JERUSALEM, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and protein replacement therapies, today announced the presentation of a poster titled "A First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome" at the 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress in Prague, Czech Republic, highlighting pharmacokinetic (PK) data relating to its oral GLP-2 analog program. 

Entera and OPKO Health, Inc. entered into a research collaboration in 2023 to develop oral peptide candidates for intestinal malabsorption syndromes, combining OPKO's proprietary long-acting GLP-2 analog (OPK-8801003) with Entera's N-Tab™ oral peptide platform. Currently, the only approved GLP-2 therapy is Gattex® (teduglutide), which generates approximately $800 million in annual sales despite requiring daily subcutaneous injections with challenging compliance rates and limited patient access.